Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Azad

Showing results (311-320 of 353) with videos related to

Pageof 36
Sort By:
Viruses|August 28, 2025
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant <i>Staphylococcus epidermidis</i> Periprosthetic Joint InfectionMelissa T Cammuso, Bradley W M Cook, D William Cameron, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaI D Davis, A Long, S Yip, et al.
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
Nature Communications|July 8, 2026
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinomaVan To, Niko Thio, Rebecca Castle, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 36

Showing results (311-320 of 353) with videos related to

Sort By:
Pageof 36
Viruses|August 28, 2025
First Use of Phage Therapy in Canada for the Treatment of a Life-Threatening, Multidrug-Resistant <i>Staphylococcus epidermidis</i> Periprosthetic Joint InfectionMelissa T Cammuso, Bradley W M Cook, D William Cameron, et al.
Molecular Oncology|January 27, 2016
Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progressionFrancesco Crea, Luca Quagliata, Agnieszka Michael, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate CancerArun A Azad, Stanislav V Volik, Alexander W Wyatt, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialNobuaki Matsubara, Arun A Azad, Neeraj Agarwal, et al.
The Lancet. Oncology|April 3, 2025
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trialAndre P Fay, Karim Fizazi, Nobuaki Matsubara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaI D Davis, A Long, S Yip, et al.
European Urology|June 4, 2020
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate CancerHeidi Fettke, Edmond M Kwan, Maria M Docanto, et al.
Nature Communications|July 8, 2026
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinomaVan To, Niko Thio, Rebecca Castle, et al.
JCO Precision Oncology|July 12, 2021
Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate CancerEdmond M Kwan, Chao Dai, Heidi Fettke, et al.
Lancet (London, England)|July 19, 2025
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialKarim Fizazi, Arun A Azad, Nobuaki Matsubara, et al.
Pageof 36